摘要
肝癌在全球具有较高的发病率和死亡率,传统形态学影像可为其诊疗提供重要的疾病解剖信息,而结合PET显像所反映的功能信息可进一步提升肿瘤的诊断准确度并辅助治疗决策。成纤维细胞激活蛋白(fibroblast activation protein,FAP)是肿瘤相关成纤维细胞的标志性蛋白,在多种上皮来源的恶性肿瘤中高表达,是肿瘤诊治的重要靶点。相较于常规应用的^(18)F-氟代脱氧葡萄糖PET显像,FAP抑制剂PET显像具有图像对比度高和不受血糖影响等优势。近年来,靶向FAP的多种放射性药物在不同肝癌类型的诊断、分期及靶向治疗等方面得到了持续拓展,本文对其相关应用进展进行综述。
Liver cancer has high morbidity and mortality worldwide.Traditional morphological imaging can offer crucial anatomical information for the diagnosis and treatment of liver cancer,and when combined with the functional data shown by PET imaging,the diagnostic accuracy of tumors can be further improved and assisted in treatment selection.Fibroblast activation protein(FAP),a signature protein of cancer-associated fibroblasts,is highly expressed in a variety of malignant tumors of epithelial origin and is an important target for tumor diagnosis and treatment.Compared with routinely applied ^(18)F-fluorodeoxyglucose(FDG)PET imaging,FAP inhibitor(FAPI)PET imaging has the advantages of high image contrast and independence from blood glucose.In recent years,a variety of radiopharmaceuticals targeting FAP have been continuously expanded in the diagnosis,staging and targeted therapy of different liver cancer types,and the progress of their related applications is reviewed in this paper.
作者
何依波
石洪成
HE Yibo;SHI Hongcheng(Department of Nuclear Medicine,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Shanghai Institute of Medical Imaging,Shanghai 200032,China;Institute of Nuclear Medicine,Fudan University,Shanghai 200032,China)
出处
《中国临床医学》
2024年第5期832-837,共6页
Chinese Journal of Clinical Medicine
基金
国家临床重点专科建设项目(YWP2022-007)。
